Devices for performing regenerative medicine therapies in a safe, simple, standardized and effective manner.
The regenerative therapy market is booming
Great dissemination potential for ease of use
Significant corporate assets of intellectual property
The devices can be used in many medical specialties
Goal min 150 k€
OVERFUNDING New goal max: 600,09 k€
Autologous regenerative therapy with adipose-derived mesenchymal stem cells has for years been a technology consideredcutting-edge and supported by enormous scientific production. In 2015, Prof. Alessandro Gennai published a surgical technique called S.E.F.F.I., which is receiving enormous interest in the surgical field because it greatly reduces the need for manipulation of harvested adipose tissue, thus safeguarding the viability of the cells to be implanted.
Some medical devices are already on the market, but they all have critical issues that do not allow their practical use except by highly qualified surgeons because they require experience in harvesting subcutaneous adipose tissue.
SEFFILINE was established in 2018 with the goal of making autologous regenerative therapy accessible to all physicians for application in various specialties. Through the invention of the guide, which was immediately patented, the goal is achieved.
In 2019, production and sale of the first and only medical device enabling autologous regenerative therapy through the use of mesenchymal stem cells of adipose origin begins. The device is all-in-one, disposable, standardized, safe and inexpensive, and can be used in medical clinics, without the need for an operating room and expensive machinery, by physicians of any specialty and without specific expertise in harvesting adipose tissue.
The regenerative potential of adipose-derived mesenchymal stem cells is extremely vast, enabling a variety of applications. Therefore, SEFFILINE has made medical devices that enable regenerative therapy in various fields:
SEFFILINE has entered into exclusive distribution agreements with minimum sales contractual constraints in the following countries: Italy, United Kingdom, Australia, New Zealand, United Arab Emirates and Saudi Arabia, Indonesia, Philippines and Thailand, Brazil while contacts are in place with Poland, Spain, Germany, France, Ukraine, Israel, Jordan, Mexico, Turkey, and Russia.
At present, most of the distributors are in the process of approving products in their respective countries and training agents. SEFFILINE, through its Academy, is in charge of the selection and training of trainers, medical opinion leaders and 'ambassadors' who train medical end-customers.
© 2023 SiamoSoci Srl a company of Azimut Group - VAT number IT07464370969 - Via Timavo 34, 20124 MI - SC € 95.417,54 fully paid up - Registr. 8, resolution 19002 of 06/08/14